SG11201901747VA - Inhibitors of cellular metabolic processes - Google Patents
Inhibitors of cellular metabolic processesInfo
- Publication number
- SG11201901747VA SG11201901747VA SG11201901747VA SG11201901747VA SG11201901747VA SG 11201901747V A SG11201901747V A SG 11201901747VA SG 11201901747V A SG11201901747V A SG 11201901747VA SG 11201901747V A SG11201901747V A SG 11201901747VA SG 11201901747V A SG11201901747V A SG 11201901747VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- pct
- august
- massachusetts
- english
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/141—Esters of phosphorous acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic System
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
Abstract
NTitle: INHIBITORS OF CELLULAR METABOLIC PROCESSES O RE , R D R Y f 4 4 wherein RA, R B , R C , RD, and R E are defined herein. co O RE (IA) (57) : The present disclosure provides MAT2A inhibitor compounds that are useful as thera- peutic agents for treating malignancies, and wherein the compounds conform to general formula (IA), (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 March 2018 (08.03.2018) WIP0 I PCT 0111111010 0111 °nolo olommoo IIIII O II oimIE (10) International Publication Number WO 2018/045071 Al (51) International Patent Classification: CO7D 487/04 (2006.01) A61K 31/519 (2006.01) C07F 9/141 (2006.01) A61P 35/00 (2006.01) (21) International Application Number: PCT/US2017/049439 (22) International Filing Date: 30 August 2017 (30.08.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: PCT/CN2016/097524 31 August 2016 (31.08.2016) CN 62/548,738 22 August 2017 (22.08.2017) US (71) Applicant: AGIOS PHARMACEUTICALS, INC. [US/US]; 88 Sidney Street, Cambridge, Massachusetts 02139 (US). (72) Inventors; and (71) Applicants: KONTEATIS, Zenon D. [US/US]; 137 Southern Blvd, Chatham, New Jersey 07928 (US). SUI, Zhihua [US/US]; 31 Lincoln Avenue, Somerville, Iowa 02145 (US). TRAVINS, Jeremy M. [US/US]; 59 Flagg Road, Southborough, Massachusetts 01772 (US). YE, Zhixiong [US/CN]; No. 4 Yuyang Road, Yosemite C-2012, Shunyi District, Beijing, 101302 (CN). (74) Agent: BLACK, David W. et al.; P.O. Box 2938, Min- neapolis, Minnesota 55402 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, 1-1 TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, 1-1 EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) C
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/CN2016/097524 WO2018039972A1 (en) | 2016-08-31 | 2016-08-31 | Inhibitors of cellular metabolic processes |
| US201762548738P | 2017-08-22 | 2017-08-22 | |
| PCT/US2017/049439 WO2018045071A1 (en) | 2016-08-31 | 2017-08-30 | Inhibitors of cellular metabolic processes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201901747VA true SG11201901747VA (en) | 2019-03-28 |
Family
ID=59846695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201901747VA SG11201901747VA (en) | 2016-08-31 | 2017-08-30 | Inhibitors of cellular metabolic processes |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US10329298B2 (en) |
| EP (1) | EP3507290A1 (en) |
| JP (2) | JP6832430B2 (en) |
| KR (1) | KR102411150B1 (en) |
| CN (1) | CN109890822B (en) |
| AU (2) | AU2017319500C1 (en) |
| BR (1) | BR112019003914A2 (en) |
| CA (1) | CA3034705C (en) |
| CL (1) | CL2019000511A1 (en) |
| CO (1) | CO2019002237A2 (en) |
| CR (1) | CR20190157A (en) |
| IL (1) | IL265115B (en) |
| MA (1) | MA46092A (en) |
| MX (1) | MX2019002303A (en) |
| NI (1) | NI201900019A (en) |
| PE (1) | PE20190761A1 (en) |
| SG (1) | SG11201901747VA (en) |
| TW (1) | TWI762505B (en) |
| UA (1) | UA125852C2 (en) |
| WO (1) | WO2018045071A1 (en) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3507290A1 (en) | 2016-08-31 | 2019-07-10 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| CN111886225A (en) * | 2017-08-21 | 2020-11-03 | 纳维根公司 | ARF6 inhibitors and related methods |
| KR20200032751A (en) | 2017-09-15 | 2020-03-26 | 아두로 바이오테크, 인코포레이티드 | Pyrazolopyrimidinone compounds and uses thereof |
| US11524960B2 (en) * | 2018-03-30 | 2022-12-13 | Servier Pharmaceuticals Llc | Heterobicyclic inhibitors of MAT2A and methods of use for treating cancer |
| MX2021006841A (en) | 2018-12-10 | 2021-07-02 | Ideaya Biosciences Inc | 2-oxoquinazoline derivatives as methionine adenosyltransferase 2a inhibitors. |
| PE20212090A1 (en) | 2018-12-27 | 2021-11-04 | Les Laboratoires Servier Sas | AZA-HETEROBYCYCLIC MAT2A INHIBITORS AND METHODS OF USE TO TREAT CANCER |
| EA202191800A1 (en) * | 2018-12-27 | 2021-09-13 | Ле Лаборатуар Сервье Сас | AZHETEROBYCLIC MAT2A INHIBITORS AND METHODS OF THEIR APPLICATION FOR TARGETING ON CANCER |
| WO2020167952A1 (en) * | 2019-02-12 | 2020-08-20 | Mirati Therapeutics, Inc. | Mat2a inhibitors |
| EA202192234A1 (en) * | 2019-02-13 | 2021-11-03 | Ле Лаборатуар Сервье Сас | COMBINATION THERAPY FOR USE IN CANCER TREATMENT |
| WO2021023609A1 (en) | 2019-08-02 | 2021-02-11 | Glaxosmithkline Intellectual Property Development Limited | Combination of a type i protein arginine methyltransferase (type i prmt) inhibitor and a methionine adenosyltransferase ii alpha (mat2a) inhibitor |
| AU2020392087A1 (en) | 2019-11-25 | 2022-06-09 | Amgen Inc. | Heterocyclic compounds as Delta-5 Desaturase inhibitors and methods of use |
| WO2021139775A1 (en) * | 2020-01-10 | 2021-07-15 | 江苏先声药业有限公司 | Pyridone compound and application |
| WO2021158792A1 (en) * | 2020-02-04 | 2021-08-12 | Agios Pharmaceuticals, Inc. | Methods of treating autoimmune or inflammatory diseases or disorders |
| TW202227082A (en) * | 2020-08-12 | 2022-07-16 | 美商施維雅製藥有限公司 | Combination therapies for use in treating cancer |
| TW202227446A (en) | 2020-08-12 | 2022-07-16 | 美商施維雅製藥有限公司 | Solid state forms of an organic compound |
| WO2022063128A1 (en) * | 2020-09-24 | 2022-03-31 | 上海凌达生物医药有限公司 | Aromatic ring or arylheterocyclic pyridone compound, pharmaceutical compositions, and use thereof |
| WO2022078403A1 (en) * | 2020-10-15 | 2022-04-21 | 江苏先声药业有限公司 | Substituted pyridone compound and application |
| WO2022115521A1 (en) * | 2020-11-25 | 2022-06-02 | Servier Pharmaceuticals, Llc | (heteo)aryl substituted pyrrolo-, pyrazolo- and triazolopyridazine derivates as mat2a inhibitors |
| WO2022143864A1 (en) | 2020-12-31 | 2022-07-07 | 江苏先声药业有限公司 | Tricyclic compound and use thereof |
| WO2022189379A1 (en) | 2021-03-08 | 2022-09-15 | Technische Universität München | Treatment of coronavirus infections using sam cycle inhibitors |
| CN117396480A (en) * | 2021-03-26 | 2024-01-12 | 奥弗恩制药公司 | Pyrazolopyrimidinone compounds |
| WO2023282145A1 (en) * | 2021-07-06 | 2023-01-12 | 国立研究開発法人産業技術総合研究所 | Composition for preventing or treating tissue aging |
| CN115716831A (en) * | 2021-08-25 | 2023-02-28 | 中国科学院分子细胞科学卓越创新中心 | MAT2A inhibitor and application thereof in antivirus |
| WO2023083210A1 (en) * | 2021-11-09 | 2023-05-19 | 上海海雁医药科技有限公司 | Substituted naphthyridinone derivative, and pharmaceutical composition thereof and use thereof |
| WO2023086934A1 (en) * | 2021-11-12 | 2023-05-19 | Ideaya Biosciences, Inc. | Combination therapy comprising a mat2a inhibitor and a taxane |
| GB202204913D0 (en) | 2022-04-04 | 2022-05-18 | Cambridge Entpr Ltd | antiviral therapy |
| CN116425721B (en) * | 2022-12-19 | 2024-02-02 | 艾立康药业股份有限公司 | Bicyclic compounds as MAT2A inhibitors |
Family Cites Families (113)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2714880A1 (en) | 1977-04-02 | 1978-10-26 | Hoechst Ag | CEPHEMDER DERIVATIVES AND PROCESS FOR THEIR PRODUCTION |
| EP0218385B2 (en) | 1985-09-17 | 1997-05-14 | Konica Corporation | Thermally developable light-sensitive material |
| US4950585A (en) | 1987-08-18 | 1990-08-21 | Konica Corporation | Coupler for photographic use |
| JPH01271751A (en) | 1988-04-23 | 1989-10-30 | Konica Corp | Silver halide color photographic sensitive material containing novel photographic coupler |
| JPH03172839A (en) | 1989-12-01 | 1991-07-26 | Konica Corp | Novel photographing coupler |
| JPH04133055A (en) | 1990-09-25 | 1992-05-07 | Konica Corp | Silver halide color photographic sensitive material improved in color reproducibility |
| US5356897A (en) | 1991-09-09 | 1994-10-18 | Fujisawa Pharmaceutical Co., Ltd. | 3-(heteroaryl)-pyrazololi[1,5-a]pyrimidines |
| JPH05125079A (en) | 1991-11-05 | 1993-05-21 | Otsuka Pharmaceut Factory Inc | Pyrazolo(1,5-a)pyrimidine derivative |
| JPH07253630A (en) | 1994-03-15 | 1995-10-03 | Konica Corp | Direct positive silver halide color photographic sensitive material and formation of direct positive color image |
| CA2217778A1 (en) | 1995-05-09 | 1996-11-14 | Basf Aktiengesellschaft | Pyrazolo(1,5a)pyrimidines, their preparation and their use |
| JPH08325248A (en) | 1995-05-26 | 1996-12-10 | Chugoku Kayaku Kk | New reagent for synthesizing tetrazole compound and production of tetrazole compound using the same |
| FR2746309B1 (en) | 1996-03-22 | 1998-04-17 | Oreal | COMPOSITION FOR DYEING KERATIN FIBERS CONTAINING PYRAZOLOPYRIMIDINEOXO; THEIR USE FOR DYEING AS COUPLER, DYEING PROCESSES |
| FR2750048B1 (en) | 1996-06-21 | 1998-08-14 | Oreal | KERATIN FIBER DYEING COMPOSITIONS CONTAINING PYRAZOLO- (1, 5-A) -PYRIMIDINE DERIVATIVES, DYEING PROCESS, NOVEL PYRAZOLO- (1, 5-A) -PYRIMIDINE DERIVATIVES AND THEIR PREPARATION METHOD |
| US6191131B1 (en) | 1997-07-23 | 2001-02-20 | Dupont Pharmaceuticals Company | Azolo triazines and pyrimidines |
| US6060478A (en) | 1996-07-24 | 2000-05-09 | Dupont Pharmaceuticals | Azolo triazines and pyrimidines |
| US6124289A (en) | 1996-07-24 | 2000-09-26 | Dupont Pharmaceuticals Co. | Azolo triazines and pyrimidines |
| US6313124B1 (en) | 1997-07-23 | 2001-11-06 | Dupont Pharmaceuticals Company | Tetrazine bicyclic compounds |
| US5817663A (en) | 1996-10-07 | 1998-10-06 | American Cyanamid Company | Pentafluorophenylazolopyrimidines |
| ATE297904T1 (en) | 1997-04-15 | 2005-07-15 | Genentech Inc | HALO-ALKOXYCARBONYL COMPOUNDS |
| FR2767685B1 (en) | 1997-09-01 | 2004-12-17 | Oreal | COMPOSITION FOR OXIDATION DYEING OF KERATINIC FIBERS COMPRISING 2-CHLORO 6-METHYL 3-AMINOPHENOL AND AN OXIDATION BASE, AND DYEING METHOD |
| FR2779952B1 (en) | 1998-06-19 | 2000-08-04 | Oreal | TINCTORIAL COMPOSITION CONTAINING PYRAZOLO- [1,5-A] - PYRIMIDINE AS OXIDATION BASE AND PYRIDINIC COUPLER, AND DYEING METHODS |
| FR2779950B1 (en) | 1998-06-19 | 2004-05-21 | Oreal | KERATINIC FIBER OXIDATION DYE COMPOSITION AND DYEING METHOD USING THE SAME |
| FR2779948B1 (en) | 1998-06-19 | 2004-04-23 | Oreal | TINCTORIAL COMPOSITION CONTAINING 1,8-BIS- (2,5-DIAMINOPHENOXY) -3,5-DIOXAOCTANE, AN ADDITIONAL OXIDATION BASE AND A COUPLER, AND DYEING METHODS |
| FR2779949B1 (en) | 1998-06-19 | 2004-05-21 | Oreal | KERATINIC FIBER OXIDATION DYE COMPOSITION AND DYEING METHOD USING THE SAME |
| FR2779951B1 (en) | 1998-06-19 | 2004-05-21 | Oreal | TINCTORIAL COMPOSITION CONTAINING PYRAZOLO- [1,5-A] - PYRIMIDINE AS AN OXIDATION BASE AND A NAPHTHALENIC COUPLER, AND DYEING METHODS |
| US20020062529A1 (en) | 1998-06-19 | 2002-05-30 | L'oreal S.A. | Dye composition containing 1,8-bis(2,5-diaminophenoxy)-3,6-dioxaoctane, an additional oxidation base and a coupler, and dyeing processes |
| US6576420B1 (en) | 1998-06-23 | 2003-06-10 | Regents Of The University Of California | Method for early diagnosis of, and determination of prognosis in, cancer |
| JP2000089418A (en) | 1998-09-08 | 2000-03-31 | Konica Corp | Image recording material, direct positive type silver halide photographic sensitive material and image forming method |
| US6277857B1 (en) | 1998-09-25 | 2001-08-21 | American Cyanamid Company | Fungicidal 7-oxy-and 7-thio-substituted-triazolopyrimidines |
| FR2784380B1 (en) | 1998-09-25 | 2002-09-06 | American Cyanamid Co | TRIAZOLOPYRIMIDINES 7-OXY- AND 7-THIO-SUBSTITUTED FUNGICIDES |
| US6531477B1 (en) | 1998-10-13 | 2003-03-11 | Dupont Pharmaceuticals Company | 6-substituted pyrazolo [3,4-d] pyrimidin-4-ones useful as cyclin dependent kinase inhibitors |
| FR2785183B1 (en) | 1998-11-04 | 2002-04-05 | Oreal | TINCTORIAL COMPOSITION CONTAINING CATIONIC DIRECT DYE AND PYRAZOLO- [1,5-a] - PYRIMIDINE AS OXIDATION BASE, AND DYEING METHODS |
| JP2000153671A (en) | 1998-11-20 | 2000-06-06 | Fuji Photo Film Co Ltd | Heat-sensitive recording material |
| FR2791563A1 (en) | 1999-03-29 | 2000-10-06 | Oreal | KERATIN FIBER OXIDATION DYEING COMPOSITION AND DYEING METHOD USING THE SAME |
| FR2791562B1 (en) | 1999-03-29 | 2004-03-05 | Oreal | TINCTORIAL COMPOSITION CONTAINING PYRAZOLO- [1,5-A] - PYRIMIDINE AND A MONOCYCLIC POLYAMINOPYRIMIDINE AS OXIDATION BASES AND A COUPLER, AND DYEING METHODS |
| JP4193285B2 (en) | 1999-06-04 | 2008-12-10 | コニカミノルタホールディングス株式会社 | Color toner |
| EP1067165A3 (en) | 1999-07-05 | 2001-03-14 | Konica Corporation | Organic electroluminescent element |
| US6372743B1 (en) | 1999-09-30 | 2002-04-16 | Neurogen Corporation | Certain alkylene diamine-substituted pyrazlo (1,5-a)-1,5-pyrimidines and pyrazolo (1,5-a) 1,3,5-triazines |
| AU7737900A (en) | 1999-09-30 | 2001-04-30 | Neurogen Corporation | Amino substituted pyrazolo(1,5,-a)-1,5-pyrimidines and pyrazolo(1,5-a)-1,3,5-triazines |
| US20020041880A1 (en) | 2000-07-05 | 2002-04-11 | Defeo-Jones Deborah | Method of treating cancer |
| JP2002326462A (en) | 2001-04-27 | 2002-11-12 | Fuji Photo Film Co Ltd | Heat-sensitive recording material |
| FR2831055B1 (en) | 2001-10-24 | 2004-05-28 | Oreal | TINCTORIAL COMPOSITION COMPRISING AT LEAST ONE HETEROCYCLIC BASE AND 1-N- (B-HYDROXYETHYL) 4-HYDROXY INDOLE AS A COUPLER; DYEING PROCESSES |
| EP1443890B1 (en) | 2001-11-17 | 2010-01-13 | Henkel AG & Co. KGaA | Oxidation colouring agent based on bicyclic developer components |
| GB0130418D0 (en) | 2001-12-20 | 2002-02-06 | Eastman Kodak Co | Photographic elements containing a deaggregating compound and dye forming coupler |
| GB0130416D0 (en) | 2001-12-20 | 2002-02-06 | Eastman Kodak Co | Photographic elements containing a de-aggregating compound dye-forming coupler and stabilizer |
| JP2003301009A (en) | 2002-04-10 | 2003-10-21 | Konica Minolta Holdings Inc | Photopolymerization initiator, radical generation process, photopolymerizing composition, photosensitive material for preparing lithographic printing plate and preparation method of lithographic printing plate |
| EP1511751B1 (en) | 2002-06-04 | 2008-03-19 | Neogenesis Pharmaceuticals, Inc. | Pyrazolo[1,5-a]pyrimidine compounds as antiviral agents |
| CA2494700C (en) | 2002-08-26 | 2011-06-28 | Takeda Pharmaceutical Company Limited | Calcium receptor modulating compound and use thereof |
| WO2004052315A2 (en) | 2002-12-11 | 2004-06-24 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
| AU2003303094A1 (en) * | 2002-12-30 | 2004-08-13 | Exelixis, Inc. | MAT2As AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE |
| KR20050115252A (en) | 2003-02-28 | 2005-12-07 | 데이진 화-마 가부시키가이샤 | Pyrazolo[1,5-a]pyrimidine derivatives |
| US7893096B2 (en) | 2003-03-28 | 2011-02-22 | Novartis Vaccines And Diagnostics, Inc. | Use of small molecule compounds for immunopotentiation |
| US7834014B2 (en) | 2003-04-09 | 2010-11-16 | Biogen Idec Ma Inc. | A2a adenosine receptor antagonists |
| JP4795634B2 (en) | 2003-10-31 | 2011-10-19 | 出光興産株式会社 | Organic thin film transistor |
| DE10356579A1 (en) | 2003-12-04 | 2005-07-07 | Merck Patent Gmbh | amine derivatives |
| WO2005103052A1 (en) * | 2004-04-21 | 2005-11-03 | Pfizer Products Inc. | Pyrazolo [1,5-a] pyrimidin-7-one compounds and uses thereof |
| GB0516378D0 (en) | 2005-08-09 | 2005-09-14 | Eirx Therapeutics Ltd | Compound |
| RU2008112290A (en) | 2005-09-01 | 2009-10-10 | Астеллас Фарма Инк. (Jp) | PYRIDAZINONE DERIVATIVES USED FOR TREATING PAIN |
| WO2007071688A1 (en) | 2005-12-22 | 2007-06-28 | L'oréal | Composition for dyeing keratin fibres with a tetraazapentamethine cationic direct dye, a particular oxidation base and a coupler |
| CA2645018A1 (en) | 2006-03-08 | 2007-09-13 | Takeda Pharmaceutical Company Limited | Pharmaceutical combination |
| CA2643968A1 (en) | 2006-03-17 | 2007-09-27 | Wyeth | Pyrazolo[1,5-a]pyrimidine derivatives and methods of use thereof |
| EP2010505B1 (en) | 2006-03-28 | 2012-12-05 | Atir Holding S.A. | Heterocyclic compounds and uses thereof in the treatment of sexual disorders |
| WO2007118844A1 (en) | 2006-04-13 | 2007-10-25 | Basf Se | Substituted pyrazolopyrimidines, process for their preparation and their use for controlling harmful fungi and compositions comprising them |
| CA2658764A1 (en) | 2006-07-20 | 2008-01-24 | Mehmet Kahraman | Benzothiophene inhibitors of rho kinase |
| WO2008019309A1 (en) | 2006-08-04 | 2008-02-14 | Metabasis Therapeutics, Inc. | Novel inhibitors of fructose 1,6-bisphosphatase |
| WO2008046856A2 (en) | 2006-10-18 | 2008-04-24 | Basf Se | Fungicidal compositions |
| US20080176870A1 (en) | 2006-11-20 | 2008-07-24 | Bert Nolte | Heterobicyclic metalloprotease inhibitors |
| EP2094697A1 (en) | 2006-11-23 | 2009-09-02 | Novartis AG | 5-sulfanylmethyl-pyrazolo [1,5-a]pyrimidin-7-ol derivatives as cxcr2 antagonists |
| DK2114925T3 (en) * | 2006-12-22 | 2012-05-29 | Ind Res Ltd | Azetidine analogs of nucleosidase and phosphorylase inhibitors |
| JP5205794B2 (en) | 2007-04-26 | 2013-06-05 | コニカミノルタホールディングス株式会社 | Optical filter composition, optical filter, front filter for display and squarylium compound |
| WO2009017954A1 (en) | 2007-08-01 | 2009-02-05 | Phenomix Corporation | Inhibitors of jak2 kinase |
| DE102007048447A1 (en) | 2007-10-10 | 2009-04-16 | Bayer Healthcare Ag | New substituted dihydropyrazole-3-thione compounds are hypoxia inducible factor-prolyl-4-hydroxylase inhibitor, useful for preparing medicament to treat and/or prevent e.g. cardiovascular diseases, wound healing and anemia |
| DE102007049157A1 (en) | 2007-10-13 | 2009-04-16 | Bayer Healthcare Ag | New substituted 2,3-dihydro-(1,2,3)triazol-4-one compounds are hypoxia inducible factor-prolyl-4-hydroxylase inhibitor, useful for preparing medicament to treat and/or prevent e.g. cardiovascular diseases, inflammatory disease and anemia |
| US20100029657A1 (en) | 2008-02-29 | 2010-02-04 | Wyeth | Bridged, Bicyclic Heterocyclic or Spiro Bicyclic Heterocyclic Derivatives of Pyrazolo[1, 5-A]Pyrimidines, Methods for Preparation and Uses Thereof |
| EP2265603B1 (en) | 2008-03-13 | 2014-05-07 | The General Hospital Corporation | Inhibitors of the bmp signaling pathway |
| US20100204265A1 (en) | 2009-02-09 | 2010-08-12 | Genelabs Technologies, Inc. | Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections |
| US8691825B2 (en) | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
| GB0908957D0 (en) | 2009-05-22 | 2009-07-01 | Ucb Pharma Sa | Therapeutic agents |
| CN101671336B (en) * | 2009-09-23 | 2013-11-13 | 辽宁利锋科技开发有限公司 | Aromatic heterocyclic pyridine derivatives and analogs and preparation method and application thereof |
| WO2011050245A1 (en) | 2009-10-23 | 2011-04-28 | Yangbo Feng | Bicyclic heteroaryls as kinase inhibitors |
| CN102781930B (en) | 2009-12-18 | 2016-03-23 | 田边三菱制药株式会社 | Antiplatelet drug |
| US8877795B2 (en) | 2010-05-07 | 2014-11-04 | The Board Of Trustees Of The Leland Stanford Junior University | Identification of stabilizers of multimeric proteins |
| DK2576053T3 (en) | 2010-06-01 | 2018-08-06 | Exxonmobil Res & Eng Co | HYDROGEN TREATMENT CATALYSTS AND PREPARATION THEREOF |
| BR112012033117A2 (en) | 2010-06-24 | 2016-11-22 | Gilead Sciences Inc | pyrazolo [1,5-a] pyrimidines as antiviral agents |
| EP2402345A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
| EP2402344A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole fused bicyclic compounds |
| EP2402343A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazole-fused bicyclic compounds |
| EP2402337A1 (en) | 2010-06-29 | 2012-01-04 | Basf Se | Pyrazolopyridine compounds |
| CA2808543C (en) | 2010-08-20 | 2016-01-26 | Hutchison Medipharma Limited | Pyrrolopyrimidine compounds and uses thereof |
| US20140038953A1 (en) | 2011-01-21 | 2014-02-06 | The General Hospital Corporation | Compositions and methods for cardiovascular disease |
| WO2012103457A2 (en) | 2011-01-28 | 2012-08-02 | University Of Kentucky | Stilbene analogs and methods of treating cancer |
| WO2012149157A2 (en) * | 2011-04-26 | 2012-11-01 | Bioenergenix | Heterocyclic compounds for the inhibition of pask |
| WO2012147890A1 (en) | 2011-04-27 | 2012-11-01 | 持田製薬株式会社 | Novel azole derivative |
| WO2012154610A1 (en) | 2011-05-06 | 2012-11-15 | Intellikine, Llc | Reactive pi3k kinase inhibitors and uses thereof |
| RU2014120168A (en) | 2011-10-20 | 2015-11-27 | ГЛЭКСОСМИТКЛАЙН ЭлЭлСи | SUBSTITUTED Bicyclic Azaheterocycles and Analogs as Modulators of Sirtuin |
| US9474779B2 (en) | 2012-01-19 | 2016-10-25 | Agios Pharmaceuticals, Inc. | Therapeutically active compositions and their methods of use |
| JP6133907B2 (en) | 2013-01-31 | 2017-05-24 | 三井化学アグロ株式会社 | Fused ring pyrimidine compound and pest control agent containing the same |
| WO2014144455A1 (en) | 2013-03-15 | 2014-09-18 | Epizyme, Inc. | 1 -phenoxy-3-(alkylamino)-propan-2-ol derivatives as carm1 inhibitors and uses thereof |
| WO2015012328A1 (en) | 2013-07-24 | 2015-01-29 | 武田薬品工業株式会社 | Heterocyclic compound |
| CN105611933B (en) | 2013-09-05 | 2019-01-25 | 基因泰克公司 | Anti-proliferate compound |
| GB201403093D0 (en) | 2014-02-21 | 2014-04-09 | Cancer Rec Tech Ltd | Therapeutic compounds and their use |
| EP3114127B1 (en) | 2014-03-04 | 2017-11-29 | Syngenta Participations AG | Microbiocidal heterobicyclic derivatives |
| WO2015134770A1 (en) | 2014-03-07 | 2015-09-11 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Treating soft tissue via controlled drug release |
| FR3022455B1 (en) | 2014-06-20 | 2017-09-01 | Oreal | PROCESS FOR COLORING KERATIN FIBERS COMPRISING THE APPLICATION OF A PARTICULAR CYCLIC OXIDATION BASE (HETERO) IN THE ABSENCE OF OXIDANT AND IN A RICH BODY |
| FR3022454B1 (en) | 2014-06-20 | 2017-10-06 | Oreal | METHOD FOR COLORING KERATINIC FIBERS COMPRISING THE APPLICATION OF A SELF-OXIDABLE COLORANT AND A PARTICULAR CYCLIC OXIDATION BASE (HETERO) IN THE ABSENCE OF OXIDIZER |
| US20170283440A1 (en) | 2014-09-17 | 2017-10-05 | Epizyme, Inc. | Carm1 inhibitors and uses thereof |
| JP2018076234A (en) | 2015-03-16 | 2018-05-17 | 大正製薬株式会社 | Pyrazolo[1,5-a]pyrimidine compound |
| US9796722B1 (en) | 2015-10-15 | 2017-10-24 | Indiana University Research And Technology Corporation | Hepatitis B viral assembly effectors |
| US20200317674A1 (en) | 2016-06-03 | 2020-10-08 | An2H Discovery Limited | Pyrazolopyrimidine derivatives and the compositions and methods of treatment regarding the same |
| EP3507290A1 (en) | 2016-08-31 | 2019-07-10 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| WO2018039972A1 (en) | 2016-08-31 | 2018-03-08 | Agios Pharmaceuticals, Inc. | Inhibitors of cellular metabolic processes |
| EP3449918A1 (en) | 2017-09-01 | 2019-03-06 | Technische Universität Dortmund | Bmp-mimetics |
| KR20200032751A (en) | 2017-09-15 | 2020-03-26 | 아두로 바이오테크, 인코포레이티드 | Pyrazolopyrimidinone compounds and uses thereof |
-
2017
- 2017-08-30 EP EP17764997.7A patent/EP3507290A1/en active Pending
- 2017-08-30 UA UAA201902825A patent/UA125852C2/en unknown
- 2017-08-30 AU AU2017319500A patent/AU2017319500C1/en active Active
- 2017-08-30 WO PCT/US2017/049439 patent/WO2018045071A1/en unknown
- 2017-08-30 MX MX2019002303A patent/MX2019002303A/en unknown
- 2017-08-30 CN CN201780066270.4A patent/CN109890822B/en active Active
- 2017-08-30 CA CA3034705A patent/CA3034705C/en active Active
- 2017-08-30 IL IL265115A patent/IL265115B/en unknown
- 2017-08-30 BR BR112019003914A patent/BR112019003914A2/en unknown
- 2017-08-30 SG SG11201901747VA patent/SG11201901747VA/en unknown
- 2017-08-30 US US15/691,408 patent/US10329298B2/en not_active Ceased
- 2017-08-30 MA MA046092A patent/MA46092A/en unknown
- 2017-08-30 PE PE2019000437A patent/PE20190761A1/en unknown
- 2017-08-30 JP JP2019531597A patent/JP6832430B2/en active Active
- 2017-08-30 KR KR1020197009218A patent/KR102411150B1/en active IP Right Grant
- 2017-08-30 CR CR20190157A patent/CR20190157A/en unknown
- 2017-08-31 TW TW106129811A patent/TWI762505B/en active
-
2018
- 2018-12-13 US US16/219,735 patent/US10800782B2/en active Active
-
2019
- 2019-02-26 CL CL2019000511A patent/CL2019000511A1/en unknown
- 2019-02-26 NI NI201900019A patent/NI201900019A/en unknown
- 2019-03-11 CO CONC2019/0002237A patent/CO2019002237A2/en unknown
-
2020
- 2020-08-24 US US17/000,411 patent/US11325914B1/en active Active
- 2020-11-25 AU AU2020277158A patent/AU2020277158A1/en not_active Abandoned
-
2021
- 2021-02-01 JP JP2021014131A patent/JP2021073269A/en not_active Withdrawn
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201901747VA (en) | Inhibitors of cellular metabolic processes | |
| SG11201900135YA (en) | N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors | |
| SG11201805300QA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201809714TA (en) | Piperidines as menin inhibitors | |
| SG11201809064QA (en) | Chimeric neurotoxins | |
| SG11201901700UA (en) | Biaryl compounds useful as immunomodulators | |
| SG11201907544VA (en) | Jak inhibitors containing a 4-membered heterocyclic amide | |
| SG11201809344QA (en) | Process for synthesizing 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)-pyridin-3-yl)methoxy)benzaldehyde | |
| SG11201804915RA (en) | Methods for treating huntington's disease | |
| SG11201804152RA (en) | Heterocyclic compounds as immunomodulators | |
| SG11201908971RA (en) | Erbb-2 and erbb3 binding bispecific antibodies for use in the treatment f cells that have an nrg1 fusion gene | |
| SG11201803920TA (en) | Compounds and compositions useful for treating disorders related to ntrk | |
| SG11201906386XA (en) | Combination therapy involving diaryl macrocyclic compounds | |
| SG11201906959RA (en) | Aryl hydrocarbon receptor (ahr) modulator compounds | |
| SG11201407486PA (en) | Compositions and methods for modulating utrn expression | |
| SG11201909083UA (en) | Piperidines as covalent menin inhibitors | |
| SG11201901251SA (en) | Aminopyrimidines as alk inhibitors | |
| SG11201408251SA (en) | A pharmaceutical composition containing nicotinic acid and/or nicotinamide and/or tryptophan for positively influencing the intestinal microbiota | |
| SG11201901658PA (en) | Beta-lactamase inhibitor compounds | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201908114UA (en) | Pyrimidopyrimidinones useful as wee-1 kinase inhibitors | |
| SG11201907356SA (en) | Piperidine-substituted mnk inhibitors and methods related thereto | |
| SG11201906222WA (en) | Jak1 selective inhibitors | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis |